CBER Issues Electronic Lot-Release Protocol Guidance

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration today posted its final "Guidance for Industry: Providing Regulatory Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format: Lot Release Protocols."

The US Food and Drug Administration (Rockville, MD, www.fda.gov)posted its final Guidance forIndustry: Providing Regulatory Submissions to the Center for BiologicsEvaluation and Research (CBER) in Electronic Form—Lot ReleaseProtocols. The guidance, which builds on a May 1998 draft, isavailable at www.fda.gov/cber/gdlns/elotrel.htm.

Its purpose is "to provide you with recommendations for submitting lotrelease protocols showing results of applicable tests in an electronicformat, as provided in 21 CFRPart 11.1 By following these recommendations for preparation andsubmission of electronic lot release documents, you might prevent adelay in the product release processing."

The guidance prescribes a submission package that begins with a coverletter in letter in PDF (Adobe portable document format), containing:

  • A description of the submission;

  • A listing of each lot release protocol, with reference to aseparate PDF file with its corresponding filename for each;

  • A statement that the submission is computer-virus free with adescription of the software (name, version, and company) used to checkthe files for viruses;

  • The regulatory and technical point of contact for the submission;

The guidance offers detailed conventions for directory structures,naming the files (using the old DOS convention of an eight-characterfile name plus a three-character extension: FILENAME.EXT), and labelingfloppy disks and CDs.
 



Model CD Label from CBER Guidance


Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes